Dangerous viruses pose a global, persistent and unavoidable threat to humanity.

What if we could predict which variants of a virus are of greatest concern and design medicines to protect against them, a priori?

Many of the world’s most threatening viruses are continually evolving, outwitting our immune systems, outpacing efforts to develop new effective medicines and causing untold human suffering.

Our pioneering approach centers on a unique technology platform which allows us to survey the entire landscape of existing and potential viral variants to design new vaccines and antibody drugs against the most threatening variants.

Founded by Flagship Pioneering, Apriori is a leading health security company with a mission to provide humanity with variant-proof protection against rapidly-evolving viruses.


Jesse Bloom, Ph.D.

Scientific Advisor

Professor, Fred Hutch

HHMI Investigator

Arup Chakraborty, Ph.D.

Scientific Advisor and Academic Partner, Flagship Pioneering

Institute Professor at MIT

Founding Steering Committee Member, Ragon Institute

Tom DiLenge

Senior Partner, Flagship Pioneering

Global Public Policy, Regulatory & Governmental Strategy

Stephen Hahn, M.D.

CEO-Partner, Flagship Pioneering and CEO, Harbinger Health

U.S. FDA Commissioner 2019-21

Michel C. Nussenzweig, M.D., Ph.D.

Scientific Advisor

Zanvil A. Cohn and Ralph M. Steinman Professor and Senior Physician, The Rockefeller University

HHMI Investigator

Wellington Sun, M.D.

Former Head of Vaccine Strategy, Moderna

Former Director, FDA Division of Vaccines

Andrew Weber

Senior Advisor

Former Assistant U.S. Secretary of Defense